These limitations underscore the need for cautious interpretation of our findings and highlight the importance of further research with more comprehensive follow-up data and precise treatment timelines to better understand the impact of RASi on PCa aggressiveness and recurrence. The gene discussed is MMP19; the disease is posterior cortical atrophy.